TSX Movers: Athabasca, Pengrowth, Valeant

The video discusses Statoil's acquisition of oil sands operations, boosting production to 40,000 barrels a day. Pengrowth Energy sells a royalty interest for $250 million to fund the Lindbergh project's second phase. Valeant Pharmaceuticals' shares drop after Morgan Stanley cuts its investment rating due to insufficient asset sales.

What was the impact of the acquisition of Statoil's oil sands operations?

• Increased production to 40,000 barrels per day

• Decreased production to 20,000 barrels per day

• No change in production levels

• Production was halted

How much did Pengrowth Energy sell its royalty interest for?

• $500 million

• $750 million

• $250 million

• $100 million

What is the expected benefit of Pengrowth Energy's sale of its royalty interest?

• To fund a new project

• To halt the Lindbergh project

• To advance phase two of the Lindbergh project

• To pay off debts

Why did Valeant Pharmaceuticals' shares decline?

• Because of a downgrade by Morgan Stanley

• Owing to a rise in asset sales

• Due to a successful asset sale

• Due to a new product launch

What was the new price target set for Valeant Pharmaceuticals by Morgan Stanley?

• $17.00

• $20.00

• $15.00

• $10.00